Naomasa Makita

Naomasa Makita

Auto-generated profile, based on publicly available information

Naomasa Makita

Department of Cardiology Sapporo Teishinkai Hospital Sapporo Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Closed access
NMNaomasa Makita
Naomasa Makita
NYNobue Yagihara
Nobue Yagihara
Lia CrottiLia Crotti
Lia Crotti
CJChristopher Johnson
Christopher Johnson
BBBritt-Maria Beckmann
Britt-Maria Beckmann
AGAlfred L. George
Alfred L. George
Background—: Genetic predisposition to life-threatening cardiac arrhythmias such as congenital long-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) represent treatable causes of sudden cardiac death in young adults and children. Recently, mutations in calmodulin ( CALM1 , CALM2 ) have been associated with severe forms of LQTS and CPVT, with life-threatening arrhythmias occurring very early in life. Additional mutation-positive cases are needed to discern genotype–phenotype correlations associated with calmodulin mutations. Methods and Results—: We used conventional and next-generation sequencing approaches, including exome analysis, in genotype-negative LQTS probands. We identified 5 novel de novo missense mutations in CALM2 in 3 subjects with LQTS (p.N98S, p.N98I, p.D134H) and 2 subjects with clinical features of both LQTS and CPVT (p.D132E, p.Q136P). Age of onset of major symptoms (syncope or cardiac arrest) ranged from 1 to 9 years. Three of 5 probands had cardiac arrest and 1 of these subjects did not survive. The clinical severity among subjects in this series was generally less than that originally reported for CALM1 and CALM2 associated with recurrent cardiac arrest during infancy. Four of 5 probands responded to β-blocker therapy, whereas 1 subject with mutation p.Q136P died suddenly during exertion despite this treatment. Mutations affect conserved residues located within Ca 2+ -binding loops III (p.N98S, p.N98I) or IV (p.D132E, p.D134H, p.Q136P) and caused reduced Ca 2+ -binding affinity. Conclusions—: CALM2 mutations can be associated with LQTS and with overlapping features of LQTS and CPVT.

1 December 2012 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
TITaisuke Ishikawa
Taisuke Ishikawa
ASAkinori Sato
Akinori Sato
CMCherisse A. Marcou
Cherisse A. Marcou
DTDavid J. Tester
David J. Tester
MAMichael J. Ackerman
Michael J. Ackerman
AKAkinori Kimura
Akinori Kimura
Background—: Mutations in genes including SCN5A encoding the α-subunit of the cardiac sodium channel (hNav1.5) cause Brugada syndrome via altered function of cardiac ion channels, but more than two-thirds of Brugada syndrome remains pathogenetically elusive. T-tubules and sarcoplasmic reticulum are essential in excitation of cardiomyocytes, and sarcolemmal membrane-associated protein (SLMAP) is a protein of unknown function localizing at T-tubules and sarcoplasmic reticulum. Methods and Results—: We analyzed 190 unrelated Brugada syndrome patients for mutations in SLMAP . Two missense mutations, Val269Ile and Glu710Ala, were found in heterozygous state in 2 patients but were not found in healthy individuals. Membrane surface expression of hNav1.5 in the transfected cells was affected by the mutations, and silencing of mutant SLMAP by small interfering RNA rescued the surface expression of hNav1.5. Whole-cell patch-clamp recordings of hNav1.5-expressing cells transfected with mutant SLMAP confirmed the reduced hNav1.5 current. Conclusions—: The mutations in SLMAP may cause Brugada syndrome via modulating the intracellular trafficking of hNav1.5 channel.

5 June 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TITaisuke Ishikawa
Taisuke Ishikawa
HKHiroki Kimoto
Hiroki Kimoto
HMHiroyuki Mishima
Hiroyuki Mishima
KYKenichiro Yamagata
Kenichiro Yamagata
SOSoshiro Ogata
Soshiro Ogata
NMNaomasa Makita
Naomasa Makita
The prognostic value of genetic variants for predicting lethal arrhythmic events (LAEs) in Brugada syndrome (BrS) remains controversial. We investigated whether the functional curation of SCN5A variations improves prognostic predictability. Using a heterologous expression system and whole-cell patch clamping, we functionally characterized 22 variants of unknown significance (VUSs) among 55 SCN5A mutations previously curated using in silico prediction algorithms in the Japanese BrS registry (n = 415). According to the loss-of-function (LOF) properties, SCN5A mutation carriers (n = 60) were divided into two groups: LOF-SCN5A mutations and non-LOF SCN5A variations. Functionally proven LOF-SCN5A mutation carriers (n = 45) showed significantly severer electrocardiographic conduction abnormalities and worse prognosis associated with earlier manifestations of LAEs (7.9%/year) than in silico algorithm-predicted SCN5A carriers (5.1%/year) or all BrS probands (2.5%/year). Notably, non-LOF SCN5A variation carriers (n = 15) exhibited no LAEs during the follow-up period. Multivariate analysis demonstrated that only LOF-SCN5A mutations and a history of aborted cardiac arrest were significant predictors of LAEs. Gene-based association studies using whole-exome sequencing data on another independent SCN5A mutation-negative BrS cohort (n = 288) showed no significant enrichment of rare variants in 16 985 genes including 22 non-SCN5A BrS-associated genes as compared with controls (n = 372). Furthermore, rare variations of non-SCN5A BrS-associated genes did not affect LAE-free survival curves. In vitro functional validation is key to classifying the pathogenicity of SCN5A VUSs and for risk stratification of genetic predictors of LAEs. Functionally proven LOF-SCN5A mutations are genetic burdens of sudden death in BrS, but evidence for other BrS-associated genes is elusive. Among currently recognized genetic and non-genetic risk factors for Brugada syndrome, functionally validated loss-of-function SCN5A mutations are associated with worse prognosis with earlier manifestation of lethal arrhythmic events (7.9%/year) than in silico algorithm-predicted SCN5A rare variations (5.1%/year) or Brugada-type ECG (2.5%/year).

1 March 2017 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
YYYuta Yamamoto
Yuta Yamamoto
TMTakeru Makiyama
Takeru Makiyama
THTakeshi Harita
Takeshi Harita
KSKenichi Sasaki
Kenichi Sasaki
YWYimin Wuriyanghai
Yimin Wuriyanghai
TKTakeshi Kimura
Takeshi Kimura
Calmodulin is a ubiquitous Ca2+ sensor molecule encoded by three distinct calmodulin genes, CALM1–3. Recently, mutations in CALM1–3 have been reported to be associated with severe early-onset long-QT syndrome (LQTS). However, the underlying mechanism through which heterozygous calmodulin mutations lead to severe LQTS remains unknown, particularly in human cardiomyocytes. We aimed to establish an LQTS disease model associated with a CALM2 mutation (LQT15) using human induced pluripotent stem cells (hiPSCs) and to assess mutant allele-specific ablation by genome editing for the treatment of LQT15. We generated LQT15-hiPSCs from a 12-year-old boy with LQTS carrying a CALM2-N98S mutation and differentiated these hiPSCs into cardiomyocytes (LQT15-hiPSC-CMs). Action potentials (APs) and L-type Ca2+ channel (LTCC) currents in hiPSC-CMs were analyzed by the patch-clamp technique and compared with those of healthy controls. Furthermore, we performed mutant allele-specific knockout using a CRISPR-Cas9 system and analyzed electrophysiological properties. Electrophysiological analyses revealed that LQT15-hiPSC-CMs exhibited significantly lower beating rates, prolonged AP durations, and impaired inactivation of LTCC currents compared with control cells, consistent with clinical phenotypes. Notably, ablation of the mutant allele rescued the electrophysiological abnormalities of LQT15-hiPSC-CMs, indicating that the mutant allele caused dominant-negative suppression of LTCC inactivation, resulting in prolonged AP duration. We successfully recapitulated the disease phenotypes of LQT15 and revealed that inactivation of LTCC currents was impaired in CALM2-N98S hiPSC model. Additionally, allele-specific ablation using the latest genome-editing technology provided important insights into a promising therapeutic approach for inherited cardiac diseases.

1 July 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
DHDaniel Toshio Harrell
Daniel Toshio Harrell
TATakashi Ashihara
Takashi Ashihara
TITaisuke Ishikawa
Taisuke Ishikawa
ITIchiko Tominaga
Ichiko Tominaga
Andrea MazzantiAndrea Mazzanti
Andrea Mazzanti
NMNaomasa Makita
Naomasa Makita

1 March 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
XDXavier Daumy
Xavier Daumy
MAMohamed-Yassine Amarouch
Mohamed-Yassine Amarouch
PLPierre Lindenbaum
Pierre Lindenbaum
SBStéphanie Bonnaud
Stéphanie Bonnaud
ECEric Charpentier
Eric Charpentier
JSJean-Jacques Schott
Jean-Jacques Schott